Análisis del impacto presupuestario para el Sistema Nacional de Salud de la combinación fija de amlodipino 5 o 10 mg y atorvastatina 10 mg

Abstract

The BIA of a FC of atorvastatin and amlodipine shows that the use of this medication for approved indications could generate net savings for the SNS of euro9.9M for the period 2009-2011.

Budget impact analysis of medicines: updated systematic review and implications

“…Features of the health care system: 22 studies (24%) [12,13,15,16,18,19,26,33,35,48,51,54,77,81,83,84,86,88,92,93,100,102] described some type of feature of the health care system in which the analysis was performed. The most reported characteristics were universal health coverage (59%).…”

“…Perspective: 82 studies (89%) [12][13][14][15][16][17][19][20][21][22][23][24][70][71][72]77,78,[80][81][82][83][84][85][87][88][89][90][91][92][93][95][96][97][98][99][100][101][102][103] that performed BIA were focused on the budget holder. In all, the perspective of the 92 studies was broken down as follows: the public health system (59%), health insurance companies (24%), paying parties (10%), hospitals (5%), and society (2%).…”

“…Direct costs: 62 studies (67%)[12][13][14][15][16][17][18][19][20]22,24,25,[29][30][31]35,36,38,39,[41][42][43][44][45]47,48,50,[52][53][54][55][56][57][58][59][60][61][64][65][66][67]69,71,72,75,76,79,[81][82][83][84]89,[91]…”